Key statistics dashboard for Monopar Therapeutics Inc. (MNPR). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase...
Stock Data
| Price | $101.45 |
| Market Cap | $680M |
| Enterprise Value | $627.0M |
| Beta | 1.66 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -44.59 |
| Price / Book | 6.81 |
| P/S | 0.00 |
| EV/EBITDA | -33.89 |
| EV/Sales | 0.00 |
| EV/FCF | -0.19 |
| P/FCF | -0.21 |
| Earnings Yield | -2.06% |
| FCF Yield | -479.15% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -13.08% |
| Return on Assets | -13.22% |
| Return on Invested Capital | -16.89% |
| Return on Capital Employed | -16.89% |
Financial Health
| Current Ratio | 33.56 |
| Quick Ratio | 33.56 |
| Cash Ratio | 13.14 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.08% |
| Net Debt / EBITDA | 2.85 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 15.32 |
| Cash per share | 15.72 |
| FCF per share | -381.20 |
| Tangible Book Value per share | 15.32 |
| Dividend per share | 0.00 |
Related companies: AKBA · BCYC · CMPX · FDMT · FULC · GOSS · KALV
Explore sector: Healthcare · Biotechnology
More sections of MNPR: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks